Questions? Chat with the founder on WhatsApp

Chat with the founder on WhatsApp
Arthneeti
HomeRankingsIPOScreenerInstitutions
HomeRankingsIPOScreenerInstitutions
RPG Life Sciences LtdQ3 FY22Pharmaceuticals & Biotechnology
Home/Stocks/RPG Life Sciences Ltd/Q3 FY22

RPG Life Sciences Ltd Q3 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,772P/E: 38.4Market Cap: ₹4.5K CrSector: Pharmaceuticals & Biotechnology

Revenue guidance

No information is provided regarding the same in the latest conference call.

Margin guidance

No information is provided regarding the same in the latest conference call.

3 more insights locked — sign up free to unlock

Fundraise plans

No information is provided regarding the same in the latest conference call.

Order book

No information is provided regarding the same in the latest conference call.

Capex plans

No information is provided regarding the same in the latest conference call.

How does RPG Life Sciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
1RPG Life Sciences Ltd
2Pharmaceuticals & Biotechnology Company A
Rev 1Mar 2
3Pharmaceuticals & Biotechnology Company B
Rev 2Mar 1
4Pharmaceuticals & Biotechnology Company C
Rev 2Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like RPG Life Sciences Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio

Related research

Pharmaceuticals & Biotechnology peers

Abbott India Ltd · Q2 FY22Aurobindo Pharma Ltd · Q1 FY26Biocon Ltd · Q1 FY26Zydus Lifesciences Ltd · Q1 FY26Cipla · Q1 FY26
RPG Life Sciences Ltd full stock analysisPharmaceuticals & Biotechnology sectorEarnings call directoryRankings dashboard

Questions about this analysis? Chat directly with the founder — real answers about the research, not a support bot.

WhatsApp the founder

Research team or advisory firm? Get earnings-call intelligence and ranking history as research inputs for your firm.

For Institutions

Arthneeti AI

AI-powered stock analysis from earnings call transcripts. Helping Indian investors make smarter decisions with data-driven insights.

Analysis

  • Stock Rankings
  • Sectors
  • Compare Stocks
  • IPO Dashboard
  • Stock Screener
  • Earnings Call Analysis
  • Stocks Under ₹500
  • Multibaggers

Tools

  • MF Overlap Checker
  • SIP Calculator
  • CAGR Calculator
  • FD vs Equity
  • All Calculators

Resources

  • Blog
  • Weekly Digest
  • Portfolio Analysis
  • Build Portfolio
  • Earnings Calendar
  • Q1 FY27 Earnings Hub

Company

  • Pricing
  • How Our Analysis Works
  • For Institutions
  • Terms of Service
  • Privacy Policy
+91 90841 32575 support@arthneeti.com Bengaluru, India

© 2026 Arthneeti AI. All rights reserved.

AI-analyzed data from 1,500+ company earnings calls

Continue your research

Others in Pharmaceuticals & Biotechnology this season

  • Ajanta Pharma Ltd (Q4 FY26)

    Chronic therapy areas (around 50% of combined Asia and Africa branded generics market) will remain a focus. Ajanta Pharma Ltd Q4 FY26 results — Market Cap…

  • Acutaas Chemicals Ltd (Q4 FY26)

    The company has consistently guided a 25% CAGR revenue growth and is open to revising upward if business potential exceeds this (Page 17). Acutaas Chemicals…

  • Granules India Ltd (Q4 FY26)

    Capex (~INR600 crores) will support broad-based expansion, including new API facility, IT, and US distribution center. Granules India Ltd Q4 FY26 results…

  • Sudeep Pharma Ltd (Q2 FY26)

    NSS acquisition to drive European expansion with a focus on PAN-Europe growth; infant nutrition (70-75% of NSS revenue) is a key area. Sudeep Pharma Ltd Q2…

Compare:vs Sun Pharmaceutical Industries Ltdvs Divis Laboratories Ltdvs Torrent Pharma.